A citation-based method for searching scientific literature

Dahna Coupez, Pauline Hulo, Yann Touchefeu, Céline Bossard, Jaafar Bennouna. Expert Opin Biol Ther 2020
Times Cited: 7







List of co-cited articles
17 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.
Dung T Le, Tae Won Kim, Eric Van Cutsem, Ravit Geva, Dirk Jäger, Hiroki Hara, Matthew Burge, Bert O'Neil, Petr Kavan, Takayuki Yoshino,[...]. J Clin Oncol 2020
211
42

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.
Michael J Overman, Sara Lonardi, Ka Yeung Mark Wong, Heinz-Josef Lenz, Fabio Gelsomino, Massimo Aglietta, Michael A Morse, Eric Van Cutsem, Ray McDermott, Andrew Hill,[...]. J Clin Oncol 2018
751
28

Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
Emilie Picard, Chris P Verschoor, Grace W Ma, Graham Pawelec. Front Immunol 2020
55
28

Mucinous colorectal adenocarcinoma: clinical pathology and treatment options.
Cong Luo, Shuyi Cen, Guojun Ding, Wei Wu. Cancer Commun (Lond) 2019
60
28

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.
Myriam Chalabi, Lorenzo F Fanchi, Krijn K Dijkstra, José G Van den Berg, Arend G Aalbers, Karolina Sikorska, Marta Lopez-Yurda, Cecile Grootscholten, Geerard L Beets, Petur Snaebjornsson,[...]. Nat Med 2020
185
28

Understanding the tumor immune microenvironment (TIME) for effective therapy.
Mikhail Binnewies, Edward W Roberts, Kelly Kersten, Vincent Chan, Douglas F Fearon, Miriam Merad, Lisa M Coussens, Dmitry I Gabrilovich, Suzanne Ostrand-Rosenberg, Catherine C Hedrick,[...]. Nat Med 2018
28

Immunotherapy in colorectal cancer: rationale, challenges and potential.
Karuna Ganesh, Zsofia K Stadler, Andrea Cercek, Robin B Mendelsohn, Jinru Shia, Neil H Segal, Luis A Diaz. Nat Rev Gastroenterol Hepatol 2019
303
28

PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer.
Neda Yaghoubi, Arash Soltani, Kiarash Ghazvini, Seyed Mahdi Hassanian, Seyed Isaac Hashemy. Biomed Pharmacother 2019
99
28

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.
Michael J Overman, Ray McDermott, Joseph L Leach, Sara Lonardi, Heinz-Josef Lenz, Michael A Morse, Jayesh Desai, Andrew Hill, Michael Axelson, Rebecca A Moss,[...]. Lancet Oncol 2017
28

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, Kellie N Smith, Hao Wang, Bjarne R Bartlett, Laveet K Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S Luber,[...]. Science 2017
28


Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Thierry André, Kai-Keen Shiu, Tae Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis Punt, Denis Smith, Rocio Garcia-Carbonero, Manuel Benavides, Peter Gibbs,[...]. N Engl J Med 2020
265
28

Colorectal cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ann Goding Sauer, Stacey A Fedewa, Lynn F Butterly, Joseph C Anderson, Andrea Cercek, Robert A Smith, Ahmedin Jemal. CA Cancer J Clin 2020
28

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
28

The significance of microsatellite instability in colorectal cancer after controlling for clinicopathological factors.
Sanghee Kang, Younghyun Na, Sung Yup Joung, Sun Il Lee, Sang Cheul Oh, Byung Wook Min. Medicine (Baltimore) 2018
34
28

Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer.
Michael A Morse, Michael J Overman, Leighanne Hartman, Taline Khoukaz, Edith Brutcher, Heinz-Josef Lenz, Ajlan Atasoy, Tong Shangguan, Huanyu Zhao, Bassel El-Rayes. Oncologist 2019
32
28

Nivolumab for the treatment of colorectal cancer.
Kortnye Maureen Smith, Jayesh Desai. Expert Rev Anticancer Ther 2018
15
28

QSP-IO: A Quantitative Systems Pharmacology Toolbox for Mechanistic Multiscale Modeling for Immuno-Oncology Applications.
Richard J Sové, Mohammad Jafarnejad, Chen Zhao, Hanwen Wang, Huilin Ma, Aleksander S Popel. CPT Pharmacometrics Syst Pharmacol 2020
10
14

Bispecific antibodies in cancer immunotherapy.
Christoph Rader. Curr Opin Biotechnol 2020
21
14

A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer.
Mohammad Jafarnejad, Chang Gong, Edward Gabrielson, Imke H Bartelink, Paolo Vicini, Bing Wang, Rajesh Narwal, Lorin Roskos, Aleksander S Popel. AAPS J 2019
25
14

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.
Judith A Seidel, Atsushi Otsuka, Kenji Kabashima. Front Oncol 2018
412
14

TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination.
Vesna Pulko, Xin Liu, Christopher J Krco, Kimberley J Harris, Xavier Frigola, Eugene D Kwon, Haidong Dong. J Immunol 2009
82
14

A Quantitative Systems Pharmacology Model of T Cell Engager Applied to Solid Tumor.
Huilin Ma, Hanwen Wang, Richard J Sove, Mohammad Jafarnejad, Chia-Hung Tsai, Jun Wang, Craig Giragossian, Aleksander S Popel. AAPS J 2020
9
14


Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells.
Chien-Hsing Chang, Yang Wang, Rongxiu Li, Diane L Rossi, Donglin Liu, Edmund A Rossi, Thomas M Cardillo, David M Goldenberg. Cancer Res 2017
36
14

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.
Janis M Taube, Alison Klein, Julie R Brahmer, Haiying Xu, Xiaoyu Pan, Jung H Kim, Lieping Chen, Drew M Pardoll, Suzanne L Topalian, Robert A Anders. Clin Cancer Res 2014
14

New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management.
Frank Kroschinsky, Friedrich Stölzel, Simone von Bonin, Gernot Beutel, Matthias Kochanek, Michael Kiehl, Peter Schellongowski. Crit Care 2017
174
14

Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer.
André F Oliveira, Luís Bretes, Irene Furtado. Front Oncol 2019
55
14

Multiscale Agent-Based and Hybrid Modeling of the Tumor Immune Microenvironment.
Kerri-Ann Norton, Chang Gong, Samira Jamalian, Aleksander S Popel. Processes (Basel) 2019
44
14

PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments.
Anna Maria Valentini, Federica Di Pinto, Filomena Cariola, Vito Guerra, Gianluigi Giannelli, Maria Lucia Caruso, Michele Pirrelli. Oncotarget 2018
30
14

A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART®.
Alison Betts, Nahor Haddish-Berhane, Dhaval K Shah, Piet H van der Graaf, Frank Barletta, Lindsay King, Tracey Clark, Cris Kamperschroer, Adam Root, Andrea Hooper,[...]. AAPS J 2019
18
14

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
Cathy Eng, Tae Won Kim, Johanna Bendell, Guillem Argilés, Niall C Tebbutt, Maria Di Bartolomeo, Alfredo Falcone, Marwan Fakih, Mark Kozloff, Neil H Segal,[...]. Lancet Oncol 2019
160
14


Molecular Imaging of Radiolabeled Bispecific T-Cell Engager 89Zr-AMG211 Targeting CEA-Positive Tumors.
Stijn J H Waaijer, Frank J Warnders, Sabine Stienen, Matthias Friedrich, Alexander Sternjak, H Kam Cheung, Anton G T Terwisscha van Scheltinga, Carolien P Schröder, Elisabeth G E de Vries, Marjolijn N Lub-de Hooge. Clin Cancer Res 2018
15
14

PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.
Jennifer H Yearley, Christopher Gibson, Ni Yu, Christina Moon, Erin Murphy, Jonathan Juco, Jared Lunceford, Jonathan Cheng, Laura Q M Chow, Tanguy Y Seiwert,[...]. Clin Cancer Res 2017
255
14

Spotlight on protein N-terminal acetylation.
Rasmus Ree, Sylvia Varland, Thomas Arnesen. Exp Mol Med 2018
120
14

PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers.
Mark Yarchoan, Lee A Albacker, Alexander C Hopkins, Meagan Montesion, Karthikeyan Murugesan, Teena T Vithayathil, Neeha Zaidi, Nilofer S Azad, Daniel A Laheru, Garrett M Frampton,[...]. JCI Insight 2019
146
14

In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses.
Tahiro Shin, Kiyoshi Yoshimura, Takako Shin, Emily B Crafton, Haruo Tsuchiya, Franck Housseau, Haruhiko Koseki, Richard D Schulick, Lieping Chen, Drew M Pardoll. J Exp Med 2005
121
14



Development of MGD007, a gpA33 x CD3-Bispecific DART Protein for T-Cell Immunotherapy of Metastatic Colorectal Cancer.
Paul A Moore, Kalpana Shah, Yinhua Yang, Ralph Alderson, Penny Roberts, Vatana Long, Daorong Liu, Jonathan C Li, Steve Burke, Valentina Ciccarone,[...]. Mol Cancer Ther 2018
39
14

A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.
Marina Bacac, Tanja Fauti, Johannes Sam, Sara Colombetti, Tina Weinzierl, Djamila Ouaret, Walter Bodmer, Steffi Lehmann, Thomas Hofer, Ralf J Hosse,[...]. Clin Cancer Res 2016
153
14

PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer.
Ana Bocanegra, Gonzalo Fernandez-Hinojal, Miren Zuazo-Ibarra, Hugo Arasanz, Maria Jesus Garcia-Granda, Carlos Hernandez, Maria Ibañez, Berta Hernandez-Marin, Maite Martinez-Aguillo, Maria Jose Lecumberri,[...]. Int J Mol Sci 2019
31
14

Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type.
Zoran Gatalica, Carrie Snyder, Todd Maney, Anatole Ghazalpour, Daniel A Holterman, Nianqing Xiao, Peggy Overberg, Inga Rose, Gargi D Basu, Semir Vranic,[...]. Cancer Epidemiol Biomarkers Prev 2014
308
14

In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model.
Hanwen Wang, Oleg Milberg, Imke H Bartelink, Paolo Vicini, Bing Wang, Rajesh Narwal, Lorin Roskos, Cesar A Santa-Maria, Aleksander S Popel. R Soc Open Sci 2019
25
14

PD-L1 expression on immune cells is a favorable prognostic factor for vulvar squamous cell carcinoma patients.
Jacek J Sznurkowski, Anton Żawrocki, Katarzyna Sznurkowska, Rafał Pęksa, Wojciech Biernat. Oncotarget 2017
22
14

A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
Tomohiro Kikuchi, Kosaku Mimura, Hirokazu Okayama, Yuko Nakayama, Katsuharu Saito, Leo Yamada, Eisei Endo, Wataru Sakamoto, Shotaro Fujita, Hisahito Endo,[...]. Oncol Lett 2019
19
14

Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells.
Thomas Menter, Alexandar Tzankov. Front Oncol 2018
31
14

Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.
Jason Zhu, Andrew J Armstrong, Terence W Friedlander, Won Kim, Sumanta K Pal, Daniel J George, Tian Zhang. J Immunother Cancer 2018
80
14

Improving clinical trial efficiency by biomarker-guided patient selection.
Ruud Boessen, Hiddo J Lambers Heerspink, Dick De Zeeuw, Diederick E Grobbee, Rolf H H Groenwold, Kit C B Roes. Trials 2014
7
14


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.